Today: 19 July 2026
Browse Category

NYSE:ABBV 27 August 2025 - 14 December 2025

For live price, interactive charts, financials and the latest market data, visit Google Finance.
AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie Stock (ABBV) After-Hours Update: What Happened on Dec. 12, 2025—and What to Watch Before the Next Market Open

AbbVie Inc. ended Friday, December 12, 2025, modestly lower, then drifted a bit further down in after-hours trading—an unsurprising outcome on a day when U.S. equities broadly retreated and investors refocused on the macro calendar. Here’s what moved the stock after the bell, the fresh analyst notes published on 12/12, and the practical checklist market watchers are carrying into the next session. StockAnalysis+2Reuters+2
13 December 2025
·
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys” list for 2026. Barchart.com+224/7 Wall St.+2
11 December 2025
···
AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie (ABBV) Stock on November 29, 2025: Skyrizi’s Canada Win, Big-Money Flows and a Hot Valuation Debate

AbbVie Inc. heads into the final stretch of 2025 trading just below its record highs, after a powerful rally driven by immunology blockbuster drugs Skyrizi and Rinvoq. The stock closed at $227.70 on Friday, November 28, up 0.02% on the day and sitting within a 52‑week range of roughly $164 to $245. StockAnalysis+1
29 November 2025
···
AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Stock (ABBV) Today: Skyrizi’s Canada Win, Dividend Hike and Big-Money Moves — November 28, 2025

AbbVie Inc. ended Friday’s session almost unchanged, closing around $227.70 per share, up a negligible 0.02%, after earlier trading slightly in the red.StockAnalysis+2StockAnalysis+2 Even with today’s flat finish, the pharma giant remains one of 2025’s standout healthcare names, with year‑to‑date gains of roughly 30–33%, easily beating the S&P 500.Investing.com+1
28 November 2025
·
AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie (ABBV) Stock Today: Price, Analyst Views, Medicare News and New Biotech Award – November 25, 2025

AbbVie Inc. ended Tuesday, November 25, 2025, on a firmer footing, closing at $231.80, up about 1.0% on the day and recovering some of Monday’s pullback. The move came amid a flurry of fresh headlines: U.S. Medicare confirmed plans to negotiate prices on 15 expensive drugs including an AbbVie product, AbbVie launched a new biotech award program in Quebec, and analysts published both bullish and cautious takes on the stock’s valuation and growth prospects. FinancialContent
25 November 2025
·
Stocks Slip as Tech Wobble Returns; Layoffs Spike and Tariff Showdown Clouds Outlook — Stock Market Today (Nov. 6, 2025)

Stock Market Today (Nov. 11, 2025): Dow Closes at a Record as AI Shares Stumble; FTSE 100 Hits New High on BoE Cut Bets

The Dow Jones set a new record on Nov. 11, 2025, while the Nasdaq slipped as Nvidia fell after SoftBank disclosed a $5.8B stake sale. Europe rallied on rising BoE rate‑cut bets and Vodafone’s first dividend hike in years. Here’s what moved markets and what to watch before Thursday’s CPI.
11 November 2025
········
AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s Bull Run: Why This $400B Pharma Giant’s Stock Is Just Getting Started

AbbVie’s stock has been a standout performer in 2025. Shares currently hover around $228–$229, up roughly 28–30% since January and near their highest levels on recordts2.techreportify.cn. This vastly outperforms both the S&P 500 and the broader pharma industrytimesunion.comreportify.cn – a testament to investors’ optimism in AbbVie’s post-Humira strategy. The stock’s 52-week range spans from a low of about $163.8 to the recent peak around $244.8 on October 1stts2.tech.
31 October 2025
··
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie (ABBV) Stock Up 28% YTD as New Drug Wins and Analyst Upgrades Fuel Optimism

AbbVie’s stock has been a standout in 2025. Shares currently hover around $228–$229, up roughly 28% since January and near their highest levels on recorddirectorstalkinterviews.com. By comparison, the S&P 500 healthcare index is up only around half that, so AbbVie is outperforming its sector. The stock’s 52-week high was about $244.8ts2.tech, and its low in the past year was ~$163.8. Notably, AbbVie surged to a record high in mid-September after the company announced a patent settlement ensuring no U.S. generics for its key drug Rinvoq until 2037reuters.com. That news – effectively a four-year extension of exclusivity – drove a 4% one-day jump in ABBV stockreuters.com. Analysts cheered the development; J.P. Morgan’s Chris Schott said the deal gives AbbVie “several more years of runway on one of its key growth drivers,” buying time to develop other drugs ahead of major mid-2030s patent lossesreuters.com. William Blair’s Matt Phipps added it could add ~$2 billion to Rinvoq’s peak sales by protecting the franchise longerreuters.com. This optimism around AbbVie’s future revenue stream helped fuel the stock’s late-summer rally.
23 October 2025
·
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

Stock Market Today 20.10.2025

ENDEDLive coverage has endedEnded: October 22, 2025, 6:02 AM EDT Powell Hints End of Quantitative Tightening Could Boost Stocks, But Risks Linger October 21, 2025, 5:56 AM EDT. When Powell speaks, markets listen. At a recent conference, he signaled the Fed could soon pause its balance-sheet runoff, effectively winding down quantitative tightening. A close to QT would not automatically unleash quantitative easing, but it could shift monetary policy toward easier conditions and potentially support the stock market. Yet the picture is nuanced: ending QT doesn't guarantee a rally, and it could reflect a softer economy or cooling earnings. The Fed's
20 October 2025
···
AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie Stock Skyrocketing? Analysts Say This $230 Biotech Giant Is Just Getting Started

AbbVie’s stock closed at $230.88 on Oct. 10, 2025marketbeat.com. Over the prior five trading days it moved modestly: Oct. 7: $232.83; Oct. 8: $231.24; Oct. 9: $230.69; Oct. 10: $230.50investing.com. Notably, on Sept. 30 ABBV hit a 52-week high around $244.8, buoyed by regulatory filings and a sector-wide rally. From that late-September peak it has pulled back into the low-$230s as investors digest upcoming FDA news. On Oct. 1 the entire pharma sector rallied after Pfizer announced a U.S. drug-pricing dealreuters.com; AbbVie’s shares jumped ~6–8% that day as well. Technicals remain bullish, and the stock trades above bothmarketbeat.com, though momentum indicators suggest it could be oversold.
11 October 2025
··
1 … 3 4 5 6
Go toTop